SEARCH

SEARCH BY CITATION

References

  • 1
    Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity; mechanism of a lupus anticoagulant. J Clin Invest 1980; 66: 397405.
  • 2
    Exner T, Triplett DA, Taberner DA, Howard MA, Harris EN. Comparison of test methods for the lupus anticoagulants-1 (ISLA-1). Thromb Haemost 1990; 64: 47884.
  • 3
    Thiagarajan P, Pengo V. Shapiro SS. The use of dilute Russell's viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 86974.
  • 4
    Horbach DA, Van Oort E, Donders RCJM, Derksen RHWM, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus – Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 91624.
  • 5
    Wahl DG, Guillemin F, De Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus – a meta-analysis. Lupus 1997; 6: 46773.
  • 6
    Galli M. Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome? Haemostasis 2000; 30 (Suppl. 2): 5762.
  • 7
    Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 62932.
  • 8
    Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting Lupus Anticoagulant activity of anti-β2-Glycoprotein-I autoantibodies. Thromb Haemost 1999; 81: 2568.
  • 9
    Arnout J, Meijer P, Vermylen J. Lupus Anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human β2-Glycoprotein I. Thromb Haemost 1999; 81: 92934.
  • 10
    Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996; 39: 144454.
  • 11
    Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-Glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899906.
  • 12
    Balestrieri G, Tincani A, Spatola L, Allegri F, Prati E, Cattaneo R, Valesini G, Del Papa N, Meroni P. Anti-β2-Glycoprotein-I antibodies: a marker of antiphospholipid syndrome? Lupus 1995; 4: 12230.
  • 13
    Martinuzzo ME, Forastiero RR, Carreras LO. Anti-β2-Glycoprotein-I antibodies: detection and association with thrombosis. Br J Haematol 1995; 89: 397402.
  • 14
    Roubey RAS, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to β2-Glycoprotein-I and a conventional cardiolipin immunoassay. Arthritis Rheum 1996; 39: 16067.
  • 15
    Pengo V, Balestrieri G, Tincani A, Spatola L, Biasiolo A, Brocco T. Utilization of dilute Russell's Viper Venom Time to detect autoantibodies against β2-Glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thromb Haemost 1997; 77: 1236.
  • 16
    Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, Ichikawa K, Koike T, Suzuki K. Anti-β2-Glycoprotein I monoclonal antibodies with lupus anticoagulant activity enhance β2-Glycoprotein I binding to phospholipids. J Clin Invest 1997; 99: 22608.
  • 17
    Harper MF, Hayes PM, Lentz BR, Roubey AS. Characterization of β2-Glycoprotein I binding to phospholipid membranes. Thromb Haemost 1998; 80: 6104.
  • 18
    Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-Glycoprotein-I is bound to a suitable surface. Thromb Haemost 1995; 73: 2934.
  • 19
    Brandt JT, Triplett DA, Alvin B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 118590.
  • 20
    Jennings I, Kitchen S, Woods TAL, Preston FE, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from the surveys of the UK national external quality assessment scheme (NEQAS) for blood coagulation. Thromb Haemost 1997; 77: 9347.
  • 21
    Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 214957.
  • 22
    Simmelink MJ, Derksen RH, Arnout J, De Groot PG. A simple method to distinguish between β2-Glycoprotein-I- and prothrombin- dependent lupus anticoagulant. J Thromb Haemost 2003; 1: 7407.
  • 23
    Willems GM, Janssen MP, Pelsers MMAL, Comfurius P, Galli M, Zwaal RFA, Bevers EM. Role of divalency in the high-affinity binding of anticardiolipin antibody-β2-Glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 1383342.
  • 24
    Roubey RA, Eisenberg RA, Harper MF, Winfield JB. ‘Anticardiolipin’ autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipids. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 95460.